{"slideshow_credits": null, "snippet": "A Food and Drug Administration committee recommended that doctors have more freedom to use Avandia, a diabetes drug that in 2007 was linked to possible heart problems.", "abstract": "Food and Drug Administration panel votes to loosen restrictions on controversial diabetes drug Avandia, manufactured by GlaxoSmithKline, saying doctors should have more freedom to prescribe it to patients.", "section_name": "Business Day", "print_page": "5", "document_type": "article", "byline": {"person": [{"firstname": "Sabrina", "role": "reported", "lastname": "TAVERNISE", "rank": 1, "organization": ""}, {"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 2, "organization": ""}], "original": "By SABRINA TAVERNISE and KATIE THOMAS", "contributor": "Sabrina Tavernise reported from Silver Spring, Md., and Katie Thomas from New York."}, "web_url": "http://www.nytimes.com/2013/06/07/business/fda-advisers-vote-to-lift-restrictions-on-avandia.html", "lead_paragraph": "A Food and Drug Administration committee recommended that doctors have more freedom to use Avandia, a diabetes drug that in 2007 was linked to possible heart problems.", "headline": {"seo": "F.D.A. Advisers Vote to Relax Restrictions on Avandia", "main": "F.D.A. Vote Is Minor Victory for Troubled Diabetes Drug", "print_headline": "F.D.A. Advisers\u2019 Vote Is a Minor Victory for a Troubled Diabetes Drug"}, "_id": "51b10b9540e9ec65d203bbf0", "word_count": "900", "multimedia": [{"height": 126, "url": "images/2013/06/07/business/FDA/FDA-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/06/07/business/FDA/FDA-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 1000, "url": "images/2013/06/07/business/FDA/FDA-articleLarge.jpg", "legacy": {"xlarge": "images/2013/06/07/business/FDA/FDA-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "1000"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/06/07/business/FDA/FDA-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/06/07/business/FDA/FDA-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-06-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "1"}, {"value": "Avandia (Drug)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "GlaxoSmithKline PLC", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Diabetes", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Heart", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}